If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Seasoned advisory group including RNA, translation and commercialisation luminaries.

An addiction recovery group plans to increase its presence in downtown Manchester as part of an effort to address the ...

A Code Blue emergency declaration adds another layer of urgency to the work being done by homeless outreach groups throughout ...

Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

After years of lending and investing in South Florida, Michael Dell’s BDT & MSD Partners is now looking to get into ...

EQS-AFR: Merck KGaA: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements ...

Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...

Doctors may change how they treat liver cancer after drugs from AstraZeneca Plc and Merck & Co. helped some patients, marking ...

Two late-stage studies published Wednesday in The Lancet show that Astra's Imfinzi and Merck's Keytruda delayed the progress ...

Fintel reports that on January 8, 2025, Truist Securities downgraded their outlook for Merck (NYSE:MRK) from Buy to Hold.